Sublancin is an antimicrobial peptide that inhibits DNA replication, transcription, and translation without affecting membrane integrity, and suppresses glucose uptake through competition with the phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with a MIC of 0.312 μM [1][2].

Sublancin (0-500 μM, 24 h) effectively inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 15 μM, and demonstrates no cytotoxicity in RAW246.7 macrophages, mouse peritoneal macrophages, and human Caco-2 epithelial cells [1]. Cell Viability Assay [1] Cell Line: RAW246.7, Caco-2, P-Mac Concentration: 0-500 μM Incubation Time: 24 h Result: Maintained cell viability.

Sublancin (0.5-4 mg/kg, administered intraperitoneally as a single dose) enhances the condition of mice infected with MRSA by inducing IL-6 and MCP-1, while mitigating intestinal inflammation through the inhibition of NF-κB activation [1]. Animal Model: Methicillin-resistant Staphylococcus aureus infected mice [1] Dosage: 0.5-4 mg/kg Administration: ip, single dose Result: Improved survival rate, reduced body weight loss.